Metabolic Syndrome and Benign Prostatic Hyperplasia: A Nepalese Perspective
Abstract
Introduction: Metabolic syndrome is defined as the presence of at least 3 of the following parameters: (1) waist circumference ≥ 90 cm, (2) triglycerides > 150 mg/dl or treatment for hypertriglyceridemia, (3) HDL-cholesterol < 40 mg/dl or treatment for reduced HDL-cholesterol, (4) blood pressure ≥ 130/85 mmHg or current use of antihypertensive medications, (5) fasting blood glucose ≥ 110 mg/dl or previous diagnosis of type-2 diabetes mellitus. It is closely associated with many diseases and recent studies have also shown its association with benign prostatic hyperplasia and lower urinary tract symptoms. Our study aimed to investigate association between metabolic syndrome and its components with benign prostatic hyperplasia among patients managed surgically in a tertiary centre in Western Nepal.
Methods: One hundred and four patients above 50 years with benign prostatic hyperplasia managed in the department of Surgery over one year were included in the study.
Results: Twenty-seven patients had metabolic syndrome (25.96%). There was association between metabolic syndrome and mean prostate size and among components of metabolic syndrome, high serum triglyceride and low HDL Cholesterol were found to be associated. There was increase in mean prostate size with increase in number of metabolic syndrome components which was statistically significant.
Conclusion: Metabolic syndrome along with its two components, serum triglyceride and HDL Cholesterol were associated with increase in mean prostate size.
Downloads
References
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. DOI: https://doi.org/10.2337/diab.37.12.1595
Ryl A, Rotter I, Slojewski M, Jedrzychowska A, Marcinowska Z, Grabowska M, et al. Can metabolic disorders in aging men contribute to prostatic hyperplasia eligible for transurethral resection of the prostate (TURP)? Int J Environ Res Public Health. 2015;12(3):3327-42. DOI: https://doi.org/10.3390/ijerph120303327
Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int. 2014;93(2):214-9. DOI: https://doi.org/10.1159/000357760
Nandy PR, Saha S. Association between components of metabolic syndrome and prostatic enlargement: An Indian perspective. Med J Armed Forces India. 2016;72(4):350-5. DOI: https://doi.org/10.1016/j.mjafi.2016.07.005
Ryl A, Rotter I, Miazgowski T, Slojewski M, Dolegowska B, Lubkowska A, et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol Metab Syndr. 2015;7:94. DOI: https://doi.org/10.1186/s13098-015-0089-1
Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157-62. DOI: https://doi.org/10.1038/sj.pcan.4500221
Pan JG, Jiang C, Luo R, Zhou X. Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urol Int. 2014;93(1):10-6. DOI: https://doi.org/10.1159/000354026
DiBello JR, Ioannou C, Rees J, Challacombe B, Maskell J, Choudhury N, et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. BJU Int. 2016;117(5):801-8. DOI: https://doi.org/10.1111/bju.13334
Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Vignozzi L, Corona G, et al. Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol. 2017;17(1):22. DOI: https://doi.org/10.1186/s12894-017-0211-9
Basawaraj N G ADT, Ashok kumar, Srinath MG. Can sonographic prostate volume predicts prostate specific antigen(PSA)levels inblood among non prostatic carcinoma patients? International Journal of Biological & Medical Research. 2012;3(3):1895-8.
Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:2465-75. DOI: https://doi.org/10.2147/COPD.S141295
Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World J Urol. 2011;29(2):171-8. DOI: https://doi.org/10.1007/s00345-010-0638-z
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-9.
Park YW, Min SK, Lee JH. Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men. World J Mens Health. 2012;30(3):183-8. doi.org/10.1016/j.urology.2013.03.047
Zou C, Gong D, Fang N, Fan Y. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol. 2016;34(2):281-9.
Zhao S, Chen C, Chen Z, Xia M, Tang J, Shao S, et al. Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms. Urol J. 2016;13(3):2717-26. DOI: https://doi.org/10.22037/uj.v13i3.3225
Yin Z, Yang JR, Rao JM, Song W, Zhou KQ. Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men. Asian J Androl. 2015;17(5):826-30. DOI: https://doi.org/10.4103/1008-682X.148081
Wang JY, Fu YY, Kang DY. The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016;95(19):e3243. DOI: https://doi.org/10.1097/MD.0000000000003243
Copyright (c) 2018 Raj Kumar Chhetri, Suman Baral, Neeraj Thapa
This work is licensed under a Creative Commons Attribution 4.0 International License.
- The Journal of Lumbini Medical College (JLMC) publishes open access articles under the terms of the Creative Commons Attribution (CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- JLMC requires an exclusive licence to publish the article first in its journal in print and online.
- The corresponding author should read and agree to the following statement before submission of the manuscript for publication,
- License agreement
- In submitting an article to Journal of Lumbini Medical College (JLMC) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JLMC are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. If the law requires that the article be published in the public domain, I/we will notify JLMC at the time of submission, and in such cases the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication waiver.
- I, and all co-authors, agree that, if the article is editorially accepted for publication in JLMC, data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.
Please visit Creative Commons web page for details of the terms.
